

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

Amendments to the Specification:

RECEIVED  
CENTRAL FAX CENTER

APR 17 2008

Please replace paragraph [0012] with the following amended paragraph:

[0012] The present invention is a multiparameter screening method that is used for combining the contributions of atherosclerotic risk factors to the disease, predicting a total risk of the disease and a disease risk level, determining a primary cause in the disease, assessing a therapeutic efficacy and optimizing the therapeutic targets at the different stages of the disease in different individuals who require the diagnosis, prevention or treatment of atherosclerosis-related CHD or stroke, which comprises the following phases:

defining the normal as free from atherosclerosis-related coronary heart disease or stroke;  
the measured values refer to the quantities of atherosclerotic parameters to be measured;  
measuring, for an individual, having the measured values of these atherosclerotic parameters;  
the measuring, for an individual not having the disease, the normal values of these atherosclerotic parameters;  
determining the disease risks yielded by the differences between the measured values and the

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

normal values of these atherosclerotic parameters;  
adding all the disease risks ~~together so as to yield~~  
containing a total risk of the disease;  
determining a disease risk level containing the total  
risk of the disease;  
selecting an atherosclerotic risk factor related to  
an atherosclerotic parameter that is the greatest  
contribution to the total risk so as to result in  
this risk factor as a primary therapy target of  
the disease;  
determining a greater flux between the LDL mass  
transfer flux and the monocyte mass transfer flux  
so as to result in this greater flux as a primary  
cause in the disease;  
selecting a greater concentration level between the  
LDL level in serum and the CRP level in blood  
plasma so as to result in this greater level as a  
secondary therapy target of the disease;  
calculating a relative ratio between the current  
total risk from the currently measured values of  
these atherosclerotic parameters and the previous  
total risk from previously measured values of  
these parameters so as to yield this ratio as a  
therapeutic efficacy of the disease; and  
repeating the above-mentioned methods until the  
disease risk level is reduced to a normal level  
for the individual who requires the therapy to

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

prevent or to treat atherosclerosis-related CHD or stroke.

the above-mentioned methods are written as an executable computer program named the MMA.exe to be installed into a general purpose digital computer device to accomplish said methods. outputting the total risk, the risk level, the primary cause, the therapeutic target and the therapeutic efficiency to a display or a user.

Please replace paragraph [0031] with the following amended paragraph:

[0031] Step 3.1:

Substituting a measured value  $[[c_m]]C_{m1}$  of the LDL concentration parameter into (1.1)

yields  $[[J_m = Hc_m^{\frac{11}{9}}]] J_{m1} = HC_{m1}^{\frac{11}{9}}$

where  $H = A(v^3 D^{16})^{\frac{1}{27}} \left( \frac{g \cos \alpha + f u}{z} \right)^{\frac{2}{9}}$  and  $H_e = 1$  in A;

substituting a normal value  $[[c_n]]C_{n1}$  of the LDL concentration into (1.1) yields

$[[J_n = Hc_n^{\frac{11}{9}}]] J_{n1} = HC_{n1}^{\frac{11}{9}}$ ; and

calculating  $[[\frac{J_m - J_n}{J_n}]] \frac{J_{m1} - J_{n1}}{J_{n1}}$  where  $c_m \geq c_n$

yields:

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

$$\left[ \left[ R_1 = \left( \frac{c_m}{c_n} \right)^{\frac{11}{9}} - 1 \right] \right] R_1 = \left( \frac{Cm_1}{Cn_1} \right)^{\frac{11}{9}} - 1 \quad (1)$$

where  $Cm_1 \geq Cn_1$  and  $R_1$  is the disease risk caused by the LDL concentration parameter related to the atherosclerotic risk factors being an elevated LDL level in human serum, hypercholesterolemia, high-fat diet, or other risk factors that increase in the LDL level.

Please replace paragraph [0032] with the following amended paragraph:

[0032] Step 3.2:

Substituting a measured value  $[[c_m]]Cm_2$  of the CRP concentration parameter into (1.1)

yields  $[[J_m = Hc_m^{\frac{11}{9}}]] Jm_2 = H C m_2^{\frac{11}{9}}$  where

$$H = A(v^3 D^{16})^{\frac{1}{27}} \left( \frac{g \cos \alpha + f u}{z} \right)^{\frac{2}{9}};$$

substituting a normal value  $[[c_n]]Cn_2$  of the CRP concentration into (1.1) yields

$$[[J_n = Hc_n^{\frac{11}{9}}]] Jn_2 = H C n_2^{\frac{11}{9}}; \text{ and}$$

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

calculating  $\left[ \left[ \frac{J_m - J_n}{J_n} \right] \right] \frac{Jm_2 - Jn_2}{Jn_2}$  where  ~~$e_m \geq e_n$~~

yields:

$$\left[ \left[ R_2 = \left( \frac{C_m}{C_n} \right)^{\frac{11}{9}} - 1 \right] \right] R_2 = \left( \frac{Cm_2}{Cn_2} \right)^{\frac{11}{9}} - 1 \quad ([ [2] ] \underline{2.1})$$

where  $Cm_2 \geq Cn_2$  and  $R_2$  is the disease risk caused by the CRP concentration parameter related to the atherosclerotic risk factors being the systemic inflammation, infectious agents, an elevated CRP level in human blood plasma, or other risk factors that increase the CRP level.

Please replace paragraph [0033] with the following amended paragraph:

[0033] Step 3.3:

Determining an equivalent factor F between the  $R_1$  in Step 3.1 and the  $R_2$  in Step 3.2, which comprises the following two methods:

1. The first method:

Substituting the LDL diffusion coefficient  $D_L$  into (1.1) yields  $J_x = M D_L^{\frac{16}{27}}$  where

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

$$M = A c^{\frac{11}{9}} v^{\frac{3}{27}} \left( \frac{g \cos \alpha + f u}{z} \right)^{\frac{2}{9}} \text{ and } J_x = \text{the LDL mass}$$

transfer flux;

substituting the CRP diffusion coefficient  $D_c$

into (1.1) yields  $J_y = M D_c^{\frac{16}{27}}$  where  $J_y$  = the CRP mass transfer flux;

taking  $J_y D_c^{\frac{16}{27}} = J_x D_c^{\frac{16}{27}}$  so as to yield:

$$J_y = J_x F \quad (G)$$

where the equivalent factor  $F = \left( \frac{D_c}{D_l} \right)^{\frac{16}{27}}$ ; and

according to (G), the equation ([2])2.1) in Step 3.2 is rewritten as

$$[[R_2 = F \left( \left( \frac{c_m}{c_n} \right)^{\frac{11}{9}} - 1 \right)]] R_2 = F \left( \left( \frac{Cm_2}{Cn_2} \right)^{\frac{11}{9}} - 1 \right) \quad ([3])2)$$

where  $Cm_2 \geq Cn_2$  and the disease risk  $R_2$  caused by the difference between the measured value  $[[c_m]]Cm_2$  and normal value  $[[c_n]]Cn_2$  of the CRP concentration parameter corresponds to the disease risk  $R_1$  caused by the LDL concentration parameter by means of ([3])2).

2. The secondary method:

The equivalent factor  $F = 0.66$ , which will be yielded in the Step five of the DETAILED

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

DESCRIPTION OF THE INVENTION.

RECEIVED  
CENTRAL FAX CENTER

APR 17 2008

Please replace paragraph [0034] with the following amended paragraph:

[0034] Step 3.4:

Substituting a measured value  $[[P_m]]P_{m3}$  of the blood systolic pressure parameter into (1.2)

yields  $[[J_m = H_p p_m^{\frac{1}{3}}]] J_{m3} = H_p P_{m3}^{\frac{1}{3}}$  where

$$H_p = Bc^{\frac{11}{9}} T^{\frac{16}{27}} a^{\frac{2}{3}} f^{\frac{2}{9}} z^{-\frac{2}{9}};$$

substituting a normal value  $[[P_n]]P_{n3}$  of the systolic pressure into (1.2) yields

$$[[J_n = H_p p_n^{\frac{1}{3}}]] J_{n3} = H_p P_{n3}^{\frac{1}{3}}; \text{ and}$$

calculating  $[[\frac{J_m - J_n}{J_n}]] \frac{J_{m3} - J_{n3}}{J_{n3}}$  where  $p_m \geq p_n$

yields:

$$[[R_4 = \left(\frac{P_m}{P_n}\right)^{\frac{1}{3}} - 1]] R_3 = \left(\frac{P_{m3}}{P_{n3}}\right)^{\frac{1}{3}} - 1 \quad ([[4]]3)$$

where  $P_{m3} \geq P_{n3}$  and  $[[R_4]]R_3$  is the disease risk caused by the systolic pressure parameter related to atherosclerotic risk factors being an elevated level of the systolic pressure, family history of

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

hypertension, or other risk factors that  
increase in the systolic pressure.

Please replace paragraph [0035] with the following  
amended paragraph:

[0035] Step 3.5:

Substituting a measured value  $[[P_m]]P_{m_4}$  of the  
blood diastolic pressure parameter into (1.2)

yields  $[[J_m = H_p p_m^{\frac{1}{3}}]] J_{m_4} = H_p P_{m_4}^{\frac{1}{3}}$  where

$$H_p = Bc^{\frac{11}{9}} T^{\frac{16}{27}} a^{\frac{2}{3}} f^{\frac{2}{9}} z^{\frac{2}{9}};$$

substituting a normal value  $[[P_n]]P_{n_4}$  of the  
diastolic pressure into (1.2) yields

$[[J_n = H_p p_n^{\frac{1}{3}}]] J_{n_4} = H_p P_{n_4}^{\frac{1}{3}};$  and

calculating  $[[\frac{J_m - J_n}{J_n}]] \frac{J_{m_4} - J_{n_4}}{J_{n_4}}$  where  $p_m \geq p_n$

yields:

$$[[R_5 = \left(\frac{P_m}{p_n}\right)^{\frac{1}{3}} - 1]] R_4 = \left(\frac{P_{m_4}}{P_{n_4}}\right)^{\frac{1}{3}} - 1 \quad ([[5]]4)$$

where  $P_{m_4} \geq P_{n_4}$  and  $[[R_5]]R_4$  is the disease  
risk caused by the diastolic pressure  
parameter related to the atherosclerotic



Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

risk factors being an elevated level of the diastolic pressure, the family history of hypertension, or other risk factors that increase in the diastolic pressure.

Please replace paragraph [0036] with the following amended paragraph:

[0036] Step 3.6:

Substituting a measured value  $[[f_m]]Fm_5$  of the heart rate parameter into (1.2) yields

$$[[J_m = H_f f_m^{\frac{2}{9}}]] Jm_5 = H_f Fm_5^{\frac{2}{9}} \text{ where } H_f = Bc^{\frac{11}{9}} T^{\frac{16}{27}} a^{\frac{2}{3}} p^{\frac{1}{3}} z^{\frac{2}{9}};$$

substituting a normal value  $[[f_n]]Fn_5$  of the heart rate into (1.2) yields

$$[[J_n = H_f f_n^{\frac{2}{9}}]] Jn_5 = H_f Fn_5^{\frac{2}{9}}; \text{ and}$$

calculating  $[[\frac{J_m - J_n}{J_n}]] \frac{Jm_5 - Jn_5}{Jn_5}$  where  $f_m \geq f_n$

yields:

$$[[R_6 = \left(\frac{f_m}{f_n}\right)^{\frac{2}{9}} - 1]] R_5 = \left(\frac{Fm_5}{Fn_5}\right)^{\frac{2}{9}} - 1 \quad ([[6]]5)$$

where  $Fm_5 \geq Fn_5$  and  $[[R_6]]R_5$  is the disease risk caused by the heart rate parameter related to the atherosclerotic risk factors

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

being an elevated level of the heart rate,  
smoking cigarette, emotional factors such as  
depression, or other risk factors that  
increase the heart rate.

Please replace paragraph [0037] with the following  
amended paragraph:

[0037] Step 3.7:

Substituting a measured value  $[[a_m]]\underline{Am}_6$  of the  
radius parameter of arterial vessel into

(1.2) yields  $[[J_m = H_a a_m^{\frac{2}{3}}]] \underline{Jm}_6 = H_a \underline{Am}_6^{\frac{2}{3}}$  where

$$H_a = Bc^{\frac{11}{9}} T^{\frac{16}{27}} f^{\frac{2}{9}} p^{\frac{1}{3}} z^{-\frac{2}{9}};$$

substituting a normal value  $[[a_n]]\underline{An}_6$  of the  
arterial radius into (1.2) yields

$$[[J_n = H_a a_n^{\frac{2}{3}}]] \underline{Jn}_6 = H_a \underline{An}_6^{\frac{2}{3}}; \text{ and}$$

calculating  $[[\frac{J_m - J_n}{J_n}]] \underline{\frac{Jm_6 - Jn_6}{Jn_6}}$  where  $a_m \geq a_n$

yields:

$$[[R_7 = \left(\frac{a_m}{a_n}\right)^{\frac{2}{3}} - 1]] \underline{R_6} = \left(\frac{\underline{Am}_6}{\underline{An}_6}\right)^{\frac{2}{3}} - 1 \quad ([ [7] ] \underline{6})$$

where  $\underline{Am}_6 \geq \underline{An}_6$  and  $[[R_7]]\underline{R_6}$  is the disease  
risk caused by the arterial radius parameter

Appl. No. 10/810,296

Reply to Office action of April 5, 2008

Dated April 17, 2008

related to atherosclerotic risk factors being the increased radius of arterial vessels at the lesion-prone sites, or other risk factors that increase the arterial radius.

Please replace paragraph [0038] with the following amended paragraph:

[0038] Step 3.8:

Substituting a measured value  $[[T_m]]T_{m7}$  of the plasma temperature parameter into (1.2)

yields  $[[J_m = H_T T_m^{\frac{16}{27}}]] J_{m7} = H_T T_{m7}^{\frac{16}{27}}$  where

$$H_T = Bc^{\frac{11}{9}} a^{\frac{2}{3}} f^{\frac{2}{9}} p^{\frac{1}{3}} z^{-\frac{2}{9}};$$

substituting a normal value  $[[T_n]]T_{n7}$  of the plasma temperature into (1.2) yields

$$[[J_n = H_T T_n^{\frac{16}{27}}]] J_{n7} = H_T T_{n7}^{\frac{16}{27}}; \text{ and}$$

calculating  $[[\frac{J_m - J_n}{J_n}]] \frac{J_{m7} - J_{n7}}{J_{n7}}$  where  $T_m \geq T_n$

yields:

$$[[R_8 = \left(\frac{T_m}{T_n}\right)^{\frac{16}{27}} - 1]] R_7 = \left(\frac{T_{m7}}{T_{n7}}\right)^{\frac{16}{27}} - 1 \quad ([8]7)$$

where  $T_{m7} \geq T_{n7}$  and  $[[R_8]]R_7$  is the disease

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

risk caused by the plasma temperature parameter related to the atherosclerotic risk factors being the elevated temperature of the blood plasma in the region of the lesion-prone sites, the elevated body temperature-related diseases, or other risk factors that increase the plasma temperature.

Please replace paragraph [0039] with the following amended paragraph:

[0039] Step 3.9:

Substituting a measured value  $[[\alpha_m]]\alpha_{m_g}$  of the angle parameter into (1.3) yields

$$[[J_m = H_\alpha (\cos \alpha_m)^{\frac{2}{9}}]] \underline{J_{m_g} = H_\alpha (\cos \alpha_{m_g})^{\frac{2}{9}}} \text{ where}$$

$$H_\alpha = E c^{\frac{11}{9}} D^{\frac{16}{27}} z^{-\frac{2}{9}};$$

substituting a normal value  $[[\alpha_n]]\alpha_{n_g}$  of the angle into (1.3) yields

$$[[J_n = H_\alpha (\cos \alpha_n)^{\frac{2}{9}}]] \underline{J_{n_g} = H_\alpha (\cos \alpha_{n_g})^{\frac{2}{9}}}; \text{ and}$$

calculating  $[[\frac{J_m - J_n}{J_n}]] \underline{\frac{J_{m_g} - J_{n_g}}{J_{n_g}}}$  ~~where  $\alpha_n \geq \alpha_{n_g}$~~

yields:

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

$$[[R_9 = \left(\frac{\cos \alpha_n}{\cos \alpha_n}\right)^{\frac{2}{9}} - 1]] R_8 = \left(\frac{\cos \alpha_m}{\cos \alpha_n}\right)^{\frac{2}{9}} - 1 \quad ([9]18)$$

where  $\alpha_n \geq \alpha_m$ , and  $[[R_9]]R_8$  is the disease risk caused by the angle parameter related to the atherosclerotic risk factors being the reduced size of the angle between the gravity and the average velocity of blood fluid in the region of the lesion-prone sites, an acute daughter angle of arterial bifurcation, or other risk factors that reduce the angle size.

Please replace paragraph [0040] with the following amended paragraph:

[0040] Step 3.10:

Substituting a measure value  $[[Z_m]]Z_m$  of the axial position parameter of the diffusional flux into (1.1) yields  $[[J_m = H_z z_m^{-\frac{2}{9}}]] J_m = H_z Z_m^{-\frac{2}{9}}$

where  $H_z = A c^{\frac{11}{9}} (v^3 D^{16})^{\frac{1}{27}} (g \cos \alpha + f u)^{\frac{2}{9}}$ ;

substituting a normal value  $[[Z_n]]Z_n$  of the diffusional length into (1.1) yields

$[[J_n = H_z z_n^{-\frac{2}{9}}]] J_n = H_z Z_n^{-\frac{2}{9}}$ ; and

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

calculating  $\left[ \left[ \frac{J_m - J_n}{J_n} \right] \right] \frac{Jm_9 - Jn_9}{Jn_9}$  ~~where  $z_m \leq z_n$~~

yields:

$$\left[ \left[ R_{10} = \left( \frac{z_n}{z_m} \right)^{\frac{2}{9}} - 1 \right] \right] R_9 = \left( \frac{Zn_9}{Zm_9} \right)^{\frac{2}{9}} - 1 \quad ([ [10] ] 9)$$

where  $Zn_9 \geq Zm_9$ , and  $[ [R_{10}] ] R_9$  is the disease risk caused by the axial position parameter of diffusional flux related to the atherosclerotic risk factors being the reduced axial position of the diffusional flux along the inner arterial wall at the lesion-prone sites, or other risk factors that reduce the axial position.

Please replace paragraph [0041] with the following amended paragraph:

[0041] Step four:

Adding the  $R_1$  in step 3.1 and the  $R_2$  in step 3.3 through the  $[ [R_{10}] ] R_9$  in step 3.10 ~~together so as to yield~~ containing a total risk of the disease comprising;

a current total risk of the disease caused by the differences between the currently

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

measured values and the normal values of the  
atherosclerotic parameters;  
a previous total risk of the disease caused by  
the differences between the previously  
measured values and the normal values of the  
atherosclerotic parameters.

Please replace paragraph [0042] with the following  
amended paragraph:

[0042] Step five:

Determining a disease risk level containing  
the total risk of the disease in Step four  
comprising;

considering the range of the LDL concentration  
in serum from 100 mg/dL to 300 mg/dL; and  
dividing the LDL risk level into the six risk  
sublevels at intervals of 33 mg/dL according  
to the guideline of LDL risk level given by  
the expert panels on US National Cholesterol  
Education Program;

considering the range of CRP concentration in  
blood plasma from 1.0 mg/L to 4.0 mg/L; and  
dividing the CRP risk level into the six risk

Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

sublevels at intervals of 0.5 mg/L according to the guideline of the CRP risk level given by American Heart Association;

calculating the ratio between the LDL range and the CRP range yields an equivalent factor  $F = 2/3 = 0.66$ ;

Substituting the  $F = 0.66$ ,  $[[c_n]]Cn_2 = 1.0$  mg/L and the six CRP measured vales that equal the interval values of six CRP risk sublevels into the equation ( $[[3]]_2$ ) in Step 3.3 respectively; and

calculating ( $[[3]]_2$ ) yields the six disease risks as the interval values of the six disease risk sublevels respectively;

doubling these interval values so as to result in the following seven disease risk sublevels caused by combining the LDL flux and the monocyte flux:  $0.84 \geq$  first disease risk level  $\geq 0.00$ ,  $1.75 \geq$  second disease risk level  $> 0.84$ ,  $2.70 \geq$  third disease risk level  $> 1.75$ ,  $3.70 \geq$  fourth disease risk level  $> 2.70$ ,  $4.70 \geq$  fifth disease risk level  $> 3.70$ ,  $5.80 \geq$  sixth disease risk level  $> 4.70$  and seventh disease risk level  $> 5.80$ ; and



Appl. No. 10/810,296  
Dated April 17, 2008

Reply to Office action of April 5, 2008

selecting a disease risk level containing the  
total risk of the disease in Step four from  
among seven of the disease risk sublevels.

RECEIVED  
CENTRAL FAX CENTER  
APR 17 2008

Please replace paragraph [0048] with the following  
amended paragraph:

[0048] Step eleven: These methods in Step three through Step nine are written as an executable computer program named the MMA.exe to be installed into a general purpose digital computer device to accomplish these methods and to output a result of these methods, call the screening report consisting a total risk, a risk level, a primary cause, a primary therapy target, a secondary therapy target and a therapeutic efficiency, to the individual who requires the therapy to prevent or treat atherosclerosis-related CHD or stroke.